Prelude Therapeutics (PRLD)
(Real Time Quote from BATS)
$2.41 USD
-0.19 (-7.31%)
Updated Sep 17, 2024 03:34 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Prelude Therapeutics Incorporated falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -121.83 | -115.44 | -111.69 | -56.93 | -27.57 |
Depreciation/Amortization & Depletion | -2.30 | 3.92 | 2.28 | 0.54 | 0.38 |
Net Change from Assets/Liabilities | -10.48 | 0.93 | 3.63 | 4.62 | 0.67 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 27.55 | 26.86 | 22.26 | 5.59 | 0.86 |
Net Cash From Operating Activities | -107.06 | -83.73 | -83.53 | -46.18 | -25.67 |
Property & Equipment | -3.51 | -3.02 | -2.32 | -0.62 | -0.78 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -31.13 | 84.71 | -261.48 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -34.65 | 81.69 | -263.80 | -0.62 | -0.78 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 136.41 | 0.82 | 165.20 | 246.50 | 29.85 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | -0.26 | -0.12 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.02 | 0.00 | -0.30 | -0.01 | 0.00 |
Net Cash from Financing Activities | 136.40 | 0.82 | 164.90 | 246.23 | 29.73 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -5.31 | -1.22 | -182.44 | 199.43 | 3.28 |
Cash at Beginning of Period | 34.65 | 35.87 | 218.31 | 18.88 | 15.60 |
Cash at End of Period | 29.34 | 34.65 | 35.87 | 218.31 | 18.88 |
Diluted Net EPS | -2.02 | -2.44 | -2.43 | -4.56 | NA |
Fiscal Year End for Prelude Therapeutics Incorporated falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -66.17 | -31.43 | -121.83 | -88.76 | -58.15 |
Depreciation/Amortization & Depletion | -2.00 | -1.12 | -2.30 | -1.56 | -0.25 |
Net Change from Assets/Liabilities | 0.86 | -5.21 | -10.48 | -14.20 | -13.27 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 12.46 | 5.96 | 27.55 | 21.03 | 13.86 |
Net Cash From Operating Activities | -54.85 | -31.79 | -107.06 | -83.49 | -57.80 |
Property & Equipment | -0.65 | -0.29 | -3.51 | -2.38 | -1.79 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 57.99 | 31.51 | -31.13 | -40.00 | -55.63 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 57.34 | 31.22 | -34.65 | -42.38 | -57.43 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.26 | 0.00 | 136.41 | 111.17 | 111.07 |
Issuance (Repayment) of Debt | -0.10 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.12 | -0.02 | -0.02 | -0.02 | 0.00 |
Net Cash from Financing Activities | 0.05 | -0.01 | 136.40 | 111.16 | 111.07 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 2.54 | -0.58 | -5.31 | -14.71 | -4.16 |
Cash at Beginning of Period | 29.34 | 29.34 | 34.65 | 34.65 | 34.65 |
Cash at End of Period | 31.87 | 28.75 | 29.34 | 19.94 | 30.49 |
Diluted Net EPS | -0.46 | -0.42 | -0.45 | -0.45 | -0.54 |